Company intelligence / Profile preview

Theralpha

France

Ownership: Private
Development stage: Other

Overview

Theralpha has advanced multiple ASIC-targeted compounds into clinical trials. As of 2014, six clinical studies had been initiated investigating ASIC involvement in various pain-related conditions, involving over 400 participants. The company's research has identified mambalgins (three-finger peptides from black mamba venom) as potential therapeutic agents that can produce pain relief comparable to morphine in preclinical models.

Therapeutic areas: ImmunologyCardiovascularNeurologyRheumatologyGastroenterology
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

THA903

Preclinical

Partnerships

Flamel Technologies (joint development agreement for controlled release formulations)

Beyond the preview

Go deeper on Theralpha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theralpha.

Explore the full profile